AbbVie Inc (ABBV)vsGrifols SA ADR (GRFS)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
GRFS
Grifols SA ADR
$7.64
+0.79%
HEALTHCARE · Cap: $5.20B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 745% more annual revenue ($62.82B vs $7.44B). ABBV leads profitability with a 5.8% profit margin vs 5.6%. GRFS appears more attractively valued with a PEG of 0.23. GRFS earns a higher WallStSmart Score of 69/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
GRFS
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+23.4%
Fair Value
$12.03
Current Price
$7.64
$4.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Earnings expanding 43.5% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
ROE of 7.6% — below average capital efficiency
5.6% margin — thin
Elevated debt levels
Revenue declined 4.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : GRFS
The strongest argument for GRFS centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.23 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : GRFS
The primary concerns for GRFS are Return on Equity, Profit Margin, Debt/Equity. Debt-to-equity of 1.77 is elevated, increasing financial risk.
Key Dynamics to Monitor
GRFS carries more volatility with a beta of 1.17 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GRFS scores higher overall (69/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Grifols SA ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?